Cargando…

New Aspects of Gene-Silencing for the Treatment of Cardiovascular Diseases

Coronary heart disease (CHD), mainly caused by atherosclerosis, represents the single leading cause of death in industrialized countries. Besides the classical interventional therapies new applications for treatment of vascular wall pathologies are appearing on the horizon. RNA interference (RNAi) r...

Descripción completa

Detalles Bibliográficos
Autores principales: Koenig, Olivia, Walker, Tobias, Perle, Nadja, Zech, Almuth, Neumann, Bernd, Schlensak, Christian, Wendel, Hans-Peter, Nolte, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816708/
https://www.ncbi.nlm.nih.gov/pubmed/24276320
http://dx.doi.org/10.3390/ph6070881
_version_ 1782477977190137856
author Koenig, Olivia
Walker, Tobias
Perle, Nadja
Zech, Almuth
Neumann, Bernd
Schlensak, Christian
Wendel, Hans-Peter
Nolte, Andrea
author_facet Koenig, Olivia
Walker, Tobias
Perle, Nadja
Zech, Almuth
Neumann, Bernd
Schlensak, Christian
Wendel, Hans-Peter
Nolte, Andrea
author_sort Koenig, Olivia
collection PubMed
description Coronary heart disease (CHD), mainly caused by atherosclerosis, represents the single leading cause of death in industrialized countries. Besides the classical interventional therapies new applications for treatment of vascular wall pathologies are appearing on the horizon. RNA interference (RNAi) represents a novel therapeutic strategy due to sequence-specific gene-silencing through the use of small interfering RNA (siRNA). The modulation of gene expression by short RNAs provides a powerful tool to theoretically silence any disease-related or disease-promoting gene of interest. In this review we outline the RNAi mechanisms, the currently used delivery systems and their possible applications to the cardiovascular system. Especially, the optimization of the targeting and transfection procedures could enhance the efficiency of siRNA delivery drastically and might open the way to clinical applicability. The new findings of the last years may show the techniques to new innovative therapies and could probably play an important role in treating CHD in the future.
format Online
Article
Text
id pubmed-3816708
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-38167082013-11-14 New Aspects of Gene-Silencing for the Treatment of Cardiovascular Diseases Koenig, Olivia Walker, Tobias Perle, Nadja Zech, Almuth Neumann, Bernd Schlensak, Christian Wendel, Hans-Peter Nolte, Andrea Pharmaceuticals (Basel) Review Coronary heart disease (CHD), mainly caused by atherosclerosis, represents the single leading cause of death in industrialized countries. Besides the classical interventional therapies new applications for treatment of vascular wall pathologies are appearing on the horizon. RNA interference (RNAi) represents a novel therapeutic strategy due to sequence-specific gene-silencing through the use of small interfering RNA (siRNA). The modulation of gene expression by short RNAs provides a powerful tool to theoretically silence any disease-related or disease-promoting gene of interest. In this review we outline the RNAi mechanisms, the currently used delivery systems and their possible applications to the cardiovascular system. Especially, the optimization of the targeting and transfection procedures could enhance the efficiency of siRNA delivery drastically and might open the way to clinical applicability. The new findings of the last years may show the techniques to new innovative therapies and could probably play an important role in treating CHD in the future. MDPI 2013-07-19 /pmc/articles/PMC3816708/ /pubmed/24276320 http://dx.doi.org/10.3390/ph6070881 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Koenig, Olivia
Walker, Tobias
Perle, Nadja
Zech, Almuth
Neumann, Bernd
Schlensak, Christian
Wendel, Hans-Peter
Nolte, Andrea
New Aspects of Gene-Silencing for the Treatment of Cardiovascular Diseases
title New Aspects of Gene-Silencing for the Treatment of Cardiovascular Diseases
title_full New Aspects of Gene-Silencing for the Treatment of Cardiovascular Diseases
title_fullStr New Aspects of Gene-Silencing for the Treatment of Cardiovascular Diseases
title_full_unstemmed New Aspects of Gene-Silencing for the Treatment of Cardiovascular Diseases
title_short New Aspects of Gene-Silencing for the Treatment of Cardiovascular Diseases
title_sort new aspects of gene-silencing for the treatment of cardiovascular diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816708/
https://www.ncbi.nlm.nih.gov/pubmed/24276320
http://dx.doi.org/10.3390/ph6070881
work_keys_str_mv AT koenigolivia newaspectsofgenesilencingforthetreatmentofcardiovasculardiseases
AT walkertobias newaspectsofgenesilencingforthetreatmentofcardiovasculardiseases
AT perlenadja newaspectsofgenesilencingforthetreatmentofcardiovasculardiseases
AT zechalmuth newaspectsofgenesilencingforthetreatmentofcardiovasculardiseases
AT neumannbernd newaspectsofgenesilencingforthetreatmentofcardiovasculardiseases
AT schlensakchristian newaspectsofgenesilencingforthetreatmentofcardiovasculardiseases
AT wendelhanspeter newaspectsofgenesilencingforthetreatmentofcardiovasculardiseases
AT nolteandrea newaspectsofgenesilencingforthetreatmentofcardiovasculardiseases